Sigma-Aldrich issues second annual "State of Translational Research Survey Report", conducted in collaboration with the American Association for the Advancement of Science (AAAS) and the Academic Drug Discovery Consortium (ADDC).

When someone you know is wearing an unfamiliar hat, you might not recognize them. Georgia Institute of Technology researchers are using just such a disguise to sneak biomaterials containing peptide signaling molecules into living animals.

The early registration dealine for the AACR Annual Meeting 2015 is this Friday!  Take advantage of the lowest prices available for this meeting that covers the full spectrum of cancer research–including basic, translational, clinical, and population research–through a variety of session formats. You will join more than 18,000 fellow attendees, be among the best and brightest researchers and clinicians in cancer research, and have the opportunity to network and form collaborations with colleagues from more than 70 countries.

Study indicates target for future drugs for measles, Ebola, RSV.

Findings pave way for research that focuses on detection and prevention.

One of the most mysterious forms of life may turn out to be a rich and untapped source of antibacterial drugs.

The new method lets researchers identify weak and previously undetectable interactions between proteins inside living cells.

UC Davis research finds walnuts slow prostate cancer growth, among other health benefits

Rutgers-led immune system research may also help reveal new asthma clues.

The custom technologies arm of Molecular Devices, a leader in bioanalytical systems for drug discovery, life science research, and bioassay development, has partnered with the Discovery Technologies team at the Roche Innovation Center Basel of Pharma Research and Early Development (pRED) to develop a high-throughput detection system for drug discovery screens employing Roche’s proprietary Ruthenium-based nanosecond time resolved fluorescence (Nano-TRF®) assays. The pRED screening teams in Basel and Shanghai are now installing the custom-developed Nano-TRF® cartridge in their existing Molecular Devices SpectraMax® Paradigm® multimode microplate readers and will receive on-demand delivery of new cartridges and continuing global technical support.

Salk research indicates a potential mechanism for cancer cells' adaptability.